

## Supplementary Materials for

### FOR THE ARTICLE

# Triphenylphosphonium analogs of chloramphenicol as dual-acting antimicrobial and antiproliferating agents

Julia A. Pavlova<sup>1</sup>, Zimfira Z. Khairullina<sup>1</sup>, Andrey G. Tereshchenkov<sup>2</sup>, Pavel A. Nazarov<sup>2,3</sup>, Dmitrii A. Lukianov<sup>4</sup>, Inna A. Volynkina<sup>5</sup>, Dmitry A. Skvortsov<sup>1</sup>, Gennady I. Makarov<sup>6</sup>, Etna Abad<sup>7</sup>, Somay Y. Murayama<sup>8</sup>, Susumu Kajiwara<sup>9</sup>, Alena Paleskava<sup>10,11</sup>, Andrey L. Konevega<sup>10,11,12</sup>, Yuri N. Antonenko<sup>2</sup>, Alex Lyakhovich<sup>13,14</sup>, Ilya A. Osterman<sup>1,4,#</sup>, Alexey A. Bogdanov<sup>1,2</sup>, and Natalia V. Sumbatyan<sup>1,2,#</sup>

<sup>1</sup> Lomonosov Moscow State University, Department of Chemistry, Leninskie Gory, 1, bldg 3, 119991 Moscow, Russia

<sup>2</sup> Lomonosov Moscow State University, A.N. Belozersky Institute of Physico-Chemical Biology, Leninskie Gory, 1, bldg 40, 119992 Moscow, Russia

<sup>3</sup> Laboratory of Molecular Genetics, Moscow Institute of Physics and Technology, Moscow Region, 141700 Dolgoprudny, Russia

<sup>4</sup> Center of Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo, 143028 Russia

<sup>5</sup> School of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119992, Russia

<sup>6</sup> South Ural State University, 454080 Chelyabinsk, Russia

<sup>7</sup> Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain

<sup>8</sup> Laboratory of Molecular Cell Biology, School of Pharmacy, Nihon University, Funabashi, Chiba 274-8555, Japan.

<sup>9</sup> School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa 226-8501, Japan

<sup>10</sup> Petersburg Nuclear Physics Institute, NRC "Kurchatov Institute", Gatchina, 188300, Russia

<sup>11</sup> Peter the Great St.Petersburg Polytechnic University, Saint Petersburg, 195251, Russia

<sup>12</sup> NRC "Kurchatov Institute", Moscow, 123182, Russia

<sup>13</sup> Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia

<sup>14</sup> Vall D'Hebron Institut de Recerca, 08035, Barcelona, Spain

# Correspondence: sumbtyan@belozersky.msu.ru (N.V.S.); i.osterman@skoltech.ru (I.A.O.)

### This file includes:

- I. Supplementary Methods
- II. Supplementary Tables (S1 and S2)
- III. Supplementary Figures (S1 and S2 with legends)

## I. SUPPLEMENTARY METHODS

### Detailed synthesis of CAM-C14-TPP

4-(*tert*-Butoxycarbonylamino)-*N*-[(1*R*,2*R*)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]butanamide (*Boc*-GABA-CAM). 792 mg (3.84 mmol) of *N,N'*-dicyclohexylcarbodiimide (DCC) was added to a cold solution of 600 mg (2.96 mmol) of 4-(*tert*-butoxycarbonylamino)butyric acid (*Boc*-GABA) and 442 mg (3.84 mmol) of *N*-hydroxysuccinimide (HOSu) in 15 ml of anhydrous DMF at 0°C. The mixture was stirred for 2h at 0°C, then overnight at 4°C. After that 736 mg (2.96 mmol) of chloramphenicol amine hydrochloride (CAM, **2**) and 516 µl (2.96 mmol) of DIPEA was added and the resulting mixture was stirred overnight at RT. The formed precipitate was filtered off, the reaction mixture was diluted with 200 ml of water, and the product was extracted with ethyl acetate (3×50 ml). Organic layer was washed with 0.05 M solution of H<sub>2</sub>SO<sub>4</sub> (3×50 ml), water

(1×50 ml), 5% solution of NaHCO<sub>3</sub> (3×50 ml), and saturated NaCl (1×30 ml). Then ethyl acetate was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated *in vacuo*. The target product was isolated from the residue by purification on silica gel column eluting with solvents system CH<sub>2</sub>Cl<sub>2</sub> : MeOH, 9:1. Yield: 946 mg (80%); TLC: R<sub>f</sub> (CHCl<sub>3</sub> : MeOH, 9:1) 0.34; LC-MS m/z calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub> (M+H)<sup>+</sup> 398.19, found 398.41; t<sub>R</sub> = 1.57 min. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz) δ (ppm) 8.18–8.11 (m, 2H, NO<sub>2</sub>-Ph<sub>ortho</sub>), 7.60–7.55 (m, 2H, NO<sub>2</sub>-Ph<sub>meta</sub>), 7.53 (d, J = 9.2 Hz, 1H, -CH-NH-C(O)-), 6.70 (t, J = 5.7 Hz, 1H, Boc-NH-), 5.83 (d, J = 4.7 Hz, 1H, -CH-OH), 5.01 (dd, J = 5.5, 4.7 Hz, 1H, -CH-OH), 4.85 (dd, J = 6.4, 4.3 Hz, 1H, -CH<sub>2</sub>-OH), 4.01–3.94 (m, 1H, -CH-NH-C(O)-), 3.54 (ddd, J = 10.4, 8.2, 6.4 Hz, 1H, -CH<sub>2</sub><sup>a</sup>-OH), 3.33–3.25 (m, 1H, -CH<sub>2</sub><sup>b</sup>-OH), 2.69 (q, J = 6.8 Hz, 2H, Boc-NH-CH<sub>2</sub>-), 1.97 (t, J = 7.4 Hz, 2H, -CH<sub>2</sub>-CH<sub>2</sub>-C(O)-), 1.44–1.38 (m, 2H, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-), 1.36 (s, 9H, -CH<sub>3</sub>). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 101 MHz) δ (ppm) 171.80 (-CH<sub>2</sub>-C(O)-), 157.69 (-O-C(O)-NH-), 152.06 (NO<sub>2</sub>-Ph<sub>ipso</sub>), 146.32 (NO<sub>2</sub>-Ph<sub>para</sub>), 127.34 (2C, NO<sub>2</sub>-Ph<sub>meta</sub>), 122.82 (2C, NO<sub>2</sub>-Ph<sub>ortho</sub>), 77.44 (-C(CH<sub>3</sub>)<sub>3</sub>), 69.33 (-CH-OH), 60.58 (-CH<sub>2</sub>-OH), 55.84 (-NH-CH-), 39.31 (-NH-CH<sub>2</sub>-), 32.66 (-CH<sub>2</sub>-C(O)-), 28.29 (3C, -CH<sub>3</sub>), 25.89 (-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-).

4-amino-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]butanamide (GABA-CAM, **6**). 10 ml of 50% (v/v) TFA solution in CH<sub>2</sub>Cl<sub>2</sub> was added to 846 mg of Boc-GABA-CAM. The mixture was stirred for 30 min at room temperature and then evaporated *in vacuo*. The target product was isolated by purification on silica gel column eluting with solvents system CH<sub>2</sub>Cl<sub>2</sub>: MeOH : NH<sub>4</sub>OH, 65:25:4. Yield: 620 mg (98%); TLC: R<sub>f</sub> (CHCl<sub>3</sub> : MeOH : NH<sub>4</sub>OH, 65:25:4) 0.20; LC-MS m/z calculated for C<sub>13</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub> (M+H)<sup>+</sup> 298.14, found 298.39; t<sub>R</sub> = 0.49 min. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz) δ (ppm) 8.15 (d, J = 8.8 Hz, 2H, NO<sub>2</sub>-Ph<sub>ortho</sub>), 7.68 (d, J = 9.2 Hz, 1H, -NH-C(O)-), 7.58 (d, J = 8.8 Hz, 2H, NO<sub>2</sub>-Ph<sub>meta</sub>), 5.92 (d, J = 5.4 Hz, 1H, -CH-OH), 5.02 (s, 1H, -CH-OH), 4.97 (br. s, 1H, -CH<sub>2</sub>-OH), 4.05–3.94 (m, 1H, -CH-NH-C(O)-), 3.56 (dd, J = 10.5, 7.9 Hz, 1H, -CH<sub>2</sub><sup>a</sup>-OH), 3.31 (dd, J = 10.5, 6.0 Hz, 1H, -CH<sub>2</sub><sup>b</sup>-OH), 2.65–2.55 (m, 2H, NH<sub>2</sub>-CH<sub>2</sub>-), 2.10 (t, J = 7.2 Hz, 2H, -CH<sub>2</sub>-CH<sub>2</sub>-C(O)-), 1.60 (p, J = 7.6 Hz, 2H, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 101 MHz) δ (ppm) 171.45 (-CH<sub>2</sub>-C(O)-), 152.13 (NO<sub>2</sub>-Ph<sub>ipso</sub>), 146.51 (NO<sub>2</sub>-Ph<sub>para</sub>), 127.51 (2C, NO<sub>2</sub>-Ph<sub>meta</sub>), 122.96 (2C, NO<sub>2</sub>-Ph<sub>ortho</sub>), 69.63 (-CH-OH), 60.77 (-CH<sub>2</sub>-OH), 56.13 (-NH-CH-), 35.50 (NH<sub>2</sub>-CH<sub>2</sub>-), 32.15 (-CH<sub>2</sub>-C(O)-), 23.47 (-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-).

N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]-4-(triphenyl)phosphoniumundecanamidobutanamide bromide (CAM-C14-TPP)

To the cold solution of 263 mg (0.5 mmol) of (10-carboxydecyl)(triphenyl)phosphonium bromide (**5**) and 58 mg (0.5 mmol) of N-hydroxysuccinimide in 7 ml of anhydrous CH<sub>2</sub>Cl<sub>2</sub> 103 mg (0.5 mmol) of DCC was added at 0°C. The mixture was stirred for 2h at 0°C and overnight at RT. Then 149 mg (0.5 mmol) of GABA-CAM (**6**) was added to the mixture and stirred for 5h at RT and overnight at 4°C. The reaction mixture was diluted with 15 ml of water and 1N aqueous HCl was added dropwise to neutral pH. Then the product was extracted with CHCl<sub>3</sub> (3×15 ml), and the combined organic extracts were washed with water (3×10 ml). Organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the volatiles were evaporated *in vacuo*. The target product was isolated on silica gel column eluting with solvents system CHCl<sub>3</sub> : MeOH : NH<sub>4</sub>OH = 65:25:4. Yield: 261 mg (65%); TLC: R<sub>f</sub> (CHCl<sub>3</sub> : MeOH : NH<sub>4</sub>OH, 65:25:4) 0.7; LC-MS m/z calculated for C<sub>42</sub>H<sub>53</sub>N<sub>3</sub>O<sub>6</sub>P (M)<sup>+</sup> 726.4, found 726.7; t<sub>R</sub> = 0.50 min; ESI-MS m/z calculated for C<sub>42</sub>H<sub>53</sub>N<sub>3</sub>O<sub>6</sub>P (M)<sup>+</sup>:

726.3667, found 726.3692.  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm) 8.12 (d,  $J = 8.8$  Hz, 2H,  $\text{NO}_2\text{-Ph}_{ortho}$ ), 7.89 (td,  $J = 7.0, 1.9$  Hz, 3H,  $\text{-Ph}_{para}$ ), 7.85–7.73 (m, 12H,  $\text{-Ph}_{ortho}$ ,  $\text{-Ph}_{meta}$ ), 7.70 (t,  $J = 5.4$  Hz, 1H,  $\text{-CH}_2\text{-NH-}$ ), 7.65 (d,  $J = 9.0$  Hz, 1H,  $\text{-CH-NH-}$ ), 7.58 (d,  $J = 8.8$  Hz, 2H,  $\text{NO}_2\text{-Ph}_{meta}$ ), 6.06 (br. s, 1H,  $\text{-CH-OH}$ ), 5.03 (d,  $J = 2.5$  Hz, 1H,  $\text{-CH-OH}$ ), 4.97–4.84 (m, 1H,  $\text{-CH}_2\text{-OH}$ ), 4.04–3.90 (m, 1H,  $\text{-CH-NH-}$ ), 3.61–3.48 (m, 3H,  $\text{Ph}_3\text{P}^+\text{-CH}_2\text{-}$ ,  $\text{-CH}_2^a\text{-OH}$ ), 3.28 (dd,  $J = 10.3, 5.8$  Hz, 1H,  $\text{-CH}_2^b\text{-OH}$ ), 2.79 (td,  $J = 12.3, 6.4$  Hz, 2H,  $\text{-NH-CH}_2\text{-}$ ), 2.06–1.89 (m, 4H,  $\text{-NH-C(O)-CH}_2\text{-}$ ), 1.76–1.56 (m, 2H,  $\text{-C(O)-CH}_2\text{-CH}_2\text{-CH}_2\text{-NH-}$ ), 1.56–1.06 (m, 16H,  $\text{-CH}_2\text{-}$ ).  $^{13}\text{C}$  NMR (DMSO- $d_6$ , 101 MHz)  $\delta$  (ppm) 171.95 ( $\text{-CH-NH-C(O)-}$ ), 171.79 ( $\text{-CH}_2\text{-NH-C(O)-}$ ), 152.21 ( $\text{NO}_2\text{-Ph}_{ipso}$ ), 146.23 ( $\text{NO}_2\text{-Ph}_{para}$ ), 134.91 (d,  $J_{C,P} = 2.9$  Hz, 3C,  $\text{-Ph}_{para}$ ), 133.61 (d,  $J_{C,P} = 10.1$  Hz, 6C,  $\text{-Ph}_{ortho}$ ), 130.27 (d,  $J_{C,P} = 12.4$  Hz, 6C,  $\text{-Ph}_{meta}$ ), 127.37 (2C,  $\text{NO}_2\text{-Ph}_{meta}$ ), 122.76 (2C,  $\text{NO}_2\text{-Ph}_{ortho}$ ), 118.62 (d,  $J_{C,P} = 85.7$  Hz, 3C,  $\text{-Ph}_{ipso}$ ), 69.35 ( $\text{-CH-OH}$ ), 60.55 ( $\text{-CH}_2\text{-OH}$ ), 55.91 ( $\text{-CH-NH-}$ ), 39.31 ( $\text{-NH-CH}_2\text{-}$ ), 37.86 and 35.42 (2C, 10- $\text{CH}_2$  and  $\text{-NH-CH}_2\text{-CH}_2\text{-CH}_2\text{-}$ ), 29.83 (d,  $J_{C,P} = 16.6$  Hz, 1C, 3- $\text{CH}_2$ ), 28.75, 28.68, and 28.09 (5C, 4, 5, 6, 7, and 8- $\text{CH}_2$ ), 25.66 and 25.29 (2C,  $\text{-NH-CH}_2\text{-CH}_2\text{-CH}_2$  and 9- $\text{CH}_2$ ), 21.74 (d,  $J_{C,P} = 4.0$  Hz, 1C, 2- $\text{CH}_2$ ), 20.14 (d,  $J_{C,P} = 49.8$  Hz, 1C, 1- $\text{CH}_2$ ).  $^{31}\text{P}$  NMR (DMSO- $d_6$ , 162 MHz)  $\delta$  (ppm) 24.00.

### NMR-data for CAM-C10-TPP

(*N*-{[(1*R*,2*R*)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino}-11-oxoundecyl)(triphenyl)phosphonium bromide (CAM-C10-TPP).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  (ppm) 8.09 (d,  $J = 8.6$  Hz, 2H,  $\text{NO}_2\text{-Ph}_{ortho}$ ), 7.86–7.70 (m, 15H,  $\text{-Ph}$ ), 7.63 (d,  $J = 8.6$  Hz, 2H,  $\text{NO}_2\text{-Ph}_{meta}$ ), 7.36 (d,  $J = 8.4$  Hz, 1H,  $\text{-NH-C(O)-}$ ), 5.70 (br. s, 1H,  $\text{-CH-OH}$ ), 5.26 (d,  $J = 3.7$  Hz, 1H,  $\text{-CH-OH}$ ), 4.62 (br. s, 1H,  $\text{-CH}_2\text{-OH}$ ), 4.22 (dddd,  $J = 8.4, 5.8, 4.7, 3.7$  Hz, 1H,  $\text{-CH-NH-}$ ), 3.82 (dd,  $J = 11.7, 5.8$  Hz, 1H,  $\text{-CH}_2^a\text{-OH}$ ), 3.66 (dd,  $J = 11.7, 4.7$  Hz, 1H,  $\text{-CH}_2^b\text{-OH}$ ), 3.47 (dt,  $J = 12.6, 7.9$  Hz, 2H, 1- $\text{CH}_2$ ), 2.17 (t,  $J = 7.2$  Hz, 2H, 10- $\text{CH}_2$ ), 1.72–1.61 (m, 2H, 2- $\text{CH}_2$ ), 1.58 (p,  $J = 7.4$  Hz, 2H, 9- $\text{CH}_2$ ), 1.47 (dp,  $J = 14.8, 7.4$  Hz, 2H, 3- $\text{CH}_2$ ), 1.36–1.03 (m, 10H, 4-, 5-, 6-, 7-, 8- $\text{CH}_2$ ).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)  $\delta$  (ppm) 174.24 (C=O), 151.10 ( $\text{NO}_2\text{-Ph}_{ipso}$ ), 146.58 ( $\text{NO}_2\text{-Ph}_{para}$ ), 135.33 (3C, d,  $J_{C,P} = 3.1$  Hz,  $\text{Ph}_{para}$ ), 133.44 (6C, d,  $J_{C,P} = 9.9$  Hz,  $\text{Ph}_{ortho}$ ), 130.64 (6C, d,  $J_{C,P} = 12.6$  Hz,  $\text{Ph}_{meta}$ ), 127.38 (2C,  $\text{NO}_2\text{-Ph}_{meta}$ ), 122.95 (2C,  $\text{NO}_2\text{-Ph}_{ortho}$ ), 118.05 (3C, d,  $J_{C,P} = 86.0$  Hz,  $\text{Ph}_{ipso}$ ), 71.63 ( $\text{-CH-OH}$ ), 62.03 ( $\text{-CH}_2\text{-OH}$ ), 56.33 ( $\text{-NH-CH-}$ ), 36.24 (10- $\text{CH}_2$ ), 30.27 (d,  $J_{C,P} = 15.8$  Hz, 3- $\text{CH}_2$ ), 28.84, 28.83, 28.77, 28.50, and 28.49 (5C, 4, 5, 6, 7, and 8- $\text{CH}_2$ ), 25.49 (9- $\text{CH}_2$ ), 22.52 (d,  $J_{C,P} = 50.7$  Hz, 1- $\text{CH}_2$ ), 22.46 (d,  $J_{C,P} = 4.5$  Hz, 2- $\text{CH}_2$ ).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 243 MHz)  $\delta$  (ppm) 23.86.

## II. SUPPLEMENTARY TABLES

**Table S1.** Occurrences of hydrogen bonds and stacking interactions of CAM-Cn-TPP, obtained by MD simulations (percent of frames). Chloramphenicol amine residue is designated as CAM, alkylated triphenylphosphonium fragment is designated as TPP and  $\gamma$ -aminobutyric acid residue of CAM-C14-TPP is designated as GABA.

Donor	Acceptor	CAM-C10-TPP	CAM-C14-TPP
Hydrogen bonds			
CAM/O <sub>3</sub> -H	G2505/O <sub>2</sub> '	–	2

CAM/O <sub>3</sub> -H	U2506/O <sup>4</sup>	–	18
CAM/O <sub>1</sub> -H	G2061/O <sup>6</sup>	–	85
CAM/O <sub>1</sub> -H	Ψ2504/O <sub>2</sub> <sup>7</sup>	93	2
GABA/N-H	A2059/N <sup>1</sup>	–	23
G2061/N <sup>1</sup> -H	CAM/O <sub>3</sub>	61	–
CAM/O <sub>3</sub> -H	G2505/O <sub>2</sub> <sup>7</sup>	–	2
Stacking interactions			
CAM	Ψ2504	80	20
CAM	U2506	15	27


<sup>1</sup> We modeled the structures of CAM-C10-TPP and CAM-C14-TPP complexes with the *E. coli* ribosome in the canonical A,A/P,P-state, by sequentially docking these compounds into the upper part of the NPET and PTC fragments of A,A/P,P-ribosome, followed by equilibrium molecular dynamics simulations and clustering the obtained conformations by the GROMOS method. Analysis of the most populated clusters combining 55% of all obtained frames for the CAM-C10-TPP complex and 75% of all obtained frames for the CAM-C14-TPP complex revealed that these compounds should be able to interact stably with the non-canonical binding site of the CHL described in [59].

**Table S2.** Suppression of the growth of CHL resistant *E. coli* strains harbouring CHL acetyltransferase (*cat*) gene by CAM-C10-TPP (MIC,  $\mu$ M)<sup>1</sup>.


	<i>Escherichia coli res</i>			
	<i>J53rif</i>	<i>C600rif/pIB55-1</i>	<i>C600rif/pIP162-1</i>	<i>C600recA naI</i>
CHL	>396	>396	>396	>396
CAM-10-TPP	110	90	>199	107
C10-TPP	110	67	93	136

<sup>1</sup> MIC values were determined using the double-dilution method. The MIC for each compound was determined in triplicate in two independent sets

### III. SUPPLEMENTARY FIGURES



**Figure S1. Original version of the Figure 2D.** Ribosome stalling by CAM-Cn-TPP on *trpL* mRNA in comparison with CHL, revealed by reverse-transcription primer-extension inhibition (toeprinting) assay in a cell-free translation system. Nucleotide sequences of *trpL* mRNA and its corresponding amino acid sequence is shown on the left. Black arrowhead marks translation arrest at the start codon, while colored arrowheads point to the drug-induced arrest sites within the coding sequences of mRNAs used. Note that due to the large size of the ribosome, the reverse transcriptase used in the toeprinting assay stops 16 nucleotides downstream of the codon located in the P-site.



**Figure S2. Triphenylphosphonium derivatives of chloramphenicol amine: CAM-C10-TPP (A) and CAM-C14-TPP (B). Atom numbering is based on [79].**